in the ShortHER phase III trial found that HER2-enriched BC tumor with mutated PIK3CA had an upregulated expression of MKI67, MYBL2, ESR1, PDCD1 and other genes, but only MYBL2 and PDCD1 were related with a better DFS (38). This evidence concerns the gene ERBB2 and breast cancer.